

1 STATE OF OKLAHOMA

2 1st Session of the 58th Legislature (2021)

3 HOUSE BILL 2800

By: Pfeiffer

4  
5  
6 AS INTRODUCED

7 An Act relating to insurance; amending Section 5,  
8 Chapter 426, O.S.L. 2019 (36 O.S. Supp. 2020, Section  
9 6962), which relates to compliance review; modifying  
10 calculation of certain insured's contribution;  
11 defining term; and providing an effective date.

12 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

13 SECTION 1. AMENDATORY Section 5, Chapter 426, O.S.L.  
14 2019 (36 O.S. Supp. 2020, Section 6962), is amended to read as  
15 follows:

16 Section 6962. A. The Oklahoma Insurance Department shall  
17 review and approve retail pharmacy network access for all pharmacy  
18 benefits managers (PBMs) to ensure compliance with Section 4 6961 of  
19 this ~~act~~ title.

20 B. A PBM, or an agent of a PBM, shall not:

21 1. Cause or knowingly permit the use of advertisement,  
22 promotion, solicitation, representation, proposal or offer that is  
23 untrue, deceptive or misleading;

1           2. Charge a pharmacist or pharmacy a fee related to the  
2 adjudication of a claim, including without limitation a fee for:

3           a. the submission of a claim,

4           b. enrollment or participation in a retail pharmacy  
5 network, or

6           c. the development or management of claims processing  
7 services or claims payment services related to  
8 participation in a retail pharmacy network;

9           3. Reimburse a pharmacy or pharmacist in the state an amount  
10 less than the amount that the PBM reimburses a pharmacy owned by or  
11 under common ownership with a PBM for providing the same covered  
12 services. The reimbursement amount paid to the pharmacy shall be  
13 equal to the reimbursement amount calculated on a per-unit basis  
14 using the same generic product identifier or generic code number  
15 paid to the PBM-owned or PBM-affiliated pharmacy;

16           4. Deny a pharmacy the opportunity to participate in any  
17 pharmacy network at preferred participation status if the pharmacy  
18 is willing to accept the terms and conditions that the PBM has  
19 established for other pharmacies as a condition of preferred network  
20 participation status;

21           5. Deny, limit or terminate a pharmacy's contract based on  
22 employment status of any employee who has an active license to  
23 dispense, despite probation status, with the State Board of  
24 Pharmacy;

1           6. Retroactively deny or reduce reimbursement for a covered  
2 service claim after returning a paid claim response as part of the  
3 adjudication of the claim, unless:

- 4           a. the original claim was submitted fraudulently, or
- 5           b. to correct errors identified in an audit, so long as  
6           the audit was conducted in compliance with Sections  
7           356.2 and 356.3 of Title 59 of the Oklahoma Statutes;  
8           or

9           7. Fail to make any payment due to a pharmacy or pharmacist for  
10 covered services properly rendered in the event a PBM terminates a  
11 pharmacy or pharmacist from a pharmacy benefits manager network.

12           C. The prohibitions under this section shall apply to contracts  
13 between pharmacy benefits managers and pharmacists or pharmacies for  
14 participation in retail pharmacy networks.

15           1. A PBM contract shall:

- 16           a. not restrict, directly or indirectly, any pharmacy  
17           that dispenses a prescription drug from informing, or  
18           penalize such pharmacy for informing, an individual of  
19           any differential between the individual's out-of-  
20           pocket cost or coverage with respect to acquisition of  
21           the drug and the amount an individual would pay to  
22           purchase the drug directly, and
- 23           b. ensure that any entity that provides pharmacy benefits  
24           management services under a contract with any such

1 health plan or health insurance coverage does not,  
2 with respect to such plan or coverage, restrict,  
3 directly or indirectly, a pharmacy that dispenses a  
4 prescription drug from informing, or penalize such  
5 pharmacy for informing, a covered individual of any  
6 differential between the individual's out-of-pocket  
7 cost under the plan or coverage with respect to  
8 acquisition of the drug and the amount an individual  
9 would pay for acquisition of the drug without using  
10 any health plan or health insurance coverage.

11 2. A pharmacy benefits manager's contract with a participating  
12 pharmacist or pharmacy shall not prohibit, restrict or limit  
13 disclosure of information to the Insurance Commissioner, law  
14 enforcement or state and federal governmental officials  
15 investigating or examining a complaint or conducting a review of a  
16 pharmacy benefits manager's compliance with the requirements under  
17 the Patient's Right to Pharmacy Choice Act.

18 3. A pharmacy benefits manager shall establish and maintain an  
19 electronic claim inquiry processing system using the National  
20 Council for Prescription Drug Programs' current standards to  
21 communicate information to pharmacies submitting claim inquiries.

22 C. 1. When calculating an insured's contribution to any out-  
23 of-pocket maximum, deductible, copayment, coinsurance, or any other  
24 cost-sharing requirement, the insurer or pharmacy benefits manager

1 shall include any cost-sharing amount paid by the insured or on the  
2 insured's behalf for a prescription drug that is either of the  
3 following:

4 a. without a generic equivalent, or

5 b. with a generic equivalent where the insured has  
6 obtained access to the prescription drug through any of  
7 the following:

8 (1) prior authorization from the insurer or pharmacy  
9 benefits manager, or

10 (2) a step therapy protocol, or

11 (3) the exception or appeals process of the insurer  
12 or pharmacy benefits manager.

13 2. For the purposes of this subsection, the term "generic  
14 equivalent" means a drug that has an identical amount of the same  
15 active ingredients in the same dosage form; meets applicable  
16 standards of strength, quality, and purity according to the United  
17 States Pharmacopeia or other nationally recognized compendium; and  
18 which, if administered in the same amount, would provide comparable  
19 therapeutic effects. For purposes of this section, the term generic  
20 equivalent does not include a drug that is listed by the United  
21 States Food and Drug Administration as having unresolved  
22 bioequivalence concerns according to the Administration's most  
23 recent publication of approved drug products with therapeutic  
24 equivalence evaluations.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

SECTION 2. This act shall become effective November 1, 2021.

58-1-6744            AMM            01/13/21